SCHEDULE: 683 Capital Discloses 5.36% Stake in Reviva Pharma
Beneficial Ownership Disclosure
683 Capital Management, LP, and Ari Zweiman have reported a 5.36% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc., primarily through common stock and exercisable warrants.
Summary
- 683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman (collectively, 'Reporting Persons') have filed a Schedule 13G.
- The Reporting Persons beneficially own an aggregate of 5,435,000 shares of Reviva Pharmaceuticals Holdings, Inc. Common Stock.
- This ownership represents approximately 5.36% of the outstanding Common Stock.
- The beneficial ownership includes 450,000 shares of Common Stock and warrants to purchase 4,985,000 shares of Common Stock that are currently exercisable.
- The percentage is calculated based on 96,337,119 shares outstanding after a recent offering, plus the 4,985,000 warrant shares held by the Reporting Persons.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of a significant institutional ownership stake, which is generally viewed as a neutral to slightly positive signal, indicating investor interest, but it does not provide performance or operational updates.
Positives
- A significant institutional investor, 683 Capital, has disclosed a substantial stake in Reviva Pharmaceuticals Holdings, Inc., which could be interpreted as a vote of confidence.
Risks
- The filing itself does not detail specific risks related to Reviva Pharmaceuticals Holdings, Inc.'s operations or financial health. The reporting persons certified that their acquisition and holding of securities are not for the purpose of changing or influencing control of the issuer.
Future Outlook
The filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Reviva Pharmaceuticals Holdings, Inc. or the reporting persons regarding the issuer's future performance or strategy.
Industry Context
This filing indicates a significant institutional investment in a pharmaceutical company, which is a common occurrence in the biotech and pharmaceutical sectors as investors seek opportunities in drug development and healthcare innovation.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional holder may influence market perception and potentially the share price.
- Management: Awareness of a large, passive institutional investor on the shareholder register.
Key Dates
| Date | Description |
|---|---|
| September 19, 2025 | Issuer's Prospectus Supplement filed pursuant to Rule 424(b)(5) for an offering. |
| September 22, 2025 | Date of event which requires the filing of this statement. |
| September 29, 2025 | Filing date of the Schedule 13G. |
Keywords
Reviva Pharmaceuticals, 683 Capital, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment, pharmaceutical, biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.